Leptomeningeal Metastases More Common in Patients With EGFR Mutations

Share this content:
Leptomeningeal metastases occur more frequently in patients with non-small cell lung cancer with EGFR mutations.
Leptomeningeal metastases occur more frequently in patients with non-small cell lung cancer with EGFR mutations.

Leptomeningeal metastases occur more frequently in patients with non-small cell lung cancer (NSCLC) with EGFR mutations, according to a study published in the Journal of Thoracic Oncology.1

Data on prognostic factors and outcomes for leptomeningeal metastases with EGFR mutations are lacking; researchers evaluated treatments and clinical outcomes of patients with NSCLC and leptomeningeal metastases.

Investigators analyzed data from 5387 patients treated at a single institution. Of those, 3.4% were diagnosed with leptomeningeal metastases.

Patients harboring EGFR mutations were more likely to have leptomeningeal metastases compared with those with wild-type EGFR (9.4% versus 1.7%; P < .001).

The median overall survival after leptomeningeal metastases was 8.7 months (95% CI, 7.3-10.1)

Among the 109 patients with common EGFR mutations and leptomeningeal metastases, the 88 patients who received kinase inhibitor therapy derived a greater overall survival benefit than others (10.0 months versus 3.3 months (P < .001), though active treatment with whole brain radiotherapy did not prolong overall survival of patients with EGFR-mutant disease.

RELATED: Gefitinib With Pemetrexed Improves PFS in Non-small Cell Lung Cancer

Kinase inhibitor therapy predicted improved survival (P < .001), while ECOG performance status predicted for poor survival (P < .001).                          

Reference

  1. Li Y-S, Jiang B-Y, Yang J-J, et al. Leptomeningeal metastases in non-small cell lung cancer patients with EGFR mutations. J Thorac Oncol. 2016 Aug 14. doi: 10.1016/j.jtho.2016.06.029 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters